DS3790
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 18, 2026
DS3790-076: A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies.
(clinicaltrialsregister.eu)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Daiichi Sankyo Inc.
First-in-human • New P1/2 trial • Hematological Malignancies • Oncology
February 04, 2026
The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
(Businesswire)
- "The trial is expected to enroll approximately 420 patients across multiple sites globally, including Asia, Europe and North America."
First-in-human • Trial status • Non-Hodgkin’s Lymphoma
November 19, 2025
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
(clinicaltrials.gov)
- P1/2 | N=420 | Recruiting | Sponsor: Daiichi Sankyo | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Hematological Malignancies • Oncology
1 to 3
Of
3
Go to page
1